B-019
- Generic Name
- B-019
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
Phase 1
Not yet recruiting
- Conditions
- Relapsed or Refractory B Cell Non Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06970496
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, China
A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
Phase 1
Recruiting
- Conditions
- Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06927466
- Locations
- 🇨🇳
Children's Hospital of Shanghai, Shanghai, China
🇨🇳Peking University People's Hospital, Beijing, China
🇨🇳The First Affiliated Hospital of Nanchang University, Nanchang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath